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Abstract
Metastasic breast cancer is the leading cause of death by malignancy in women worldwide. Tumor metastasis is a
multistep process encompassing local invasion of cancer cells at primary tumor site, intravasation into the blood
vessel, survival in systemic circulation, and extravasation across the endothelium to metastasize at a secondary site.
However, only a small percentage of circulating cancer cells initiate metastatic colonies. This fact, together with the
inaccessibility  and  structural  complexity  of  target  tissues  has  hampered  the  study  of  the  later  steps  in  cancer
metastasis.  In  addition,  most  data  are  derived  from  in  vivo  models  where  critical  steps  such  as  intravasation/
extravasation of human cancer cells are mediated by murine endothelial cells. Here, we developed a new mouse
model to study the molecular and cellular mechanisms underlying late steps of the metastatic cascade. We have
shown that a network of functional human blood vessels can be formed by co-implantation of human endothelial cells
and  mesenchymal  cells,  embedded  within  a  reconstituted  basement  membrane-like  matrix  and  inoculated
subcutaneously  into  immunodeficient  mice.  The  ability  of  circulating  cancer  cells  to  colonize  these  human
vascularized  organoids  was  next  assessed  in  an  orthotopic  model  of  human  breast  cancer  by  bioluminescent
imaging, molecular techniques and immunohistological analysis. We demonstrate that disseminated human breast
cancer  cells  efficiently  colonize  organoids  containing  a  functional  microvessel  network  composed  of  human
endothelial cells, connected to the mouse circulatory system. Human breast cancer cells could be clearly detected at
different stages of the metastatic process: initial arrest in the human microvasculature, extravasation, and growth into
avascular  micrometastases.  This  new  mouse  model  may  help  us  to  map  the  extravasation  process  with
unprecedented detail, opening the way for the identification of relevant targets for therapeutic intervention.
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Metastatic  disease  is  the  main  cause  of  death  in  breast
cancer  patients  [1].  Hematogenous  cancer  metastasis  is  a
multistep process encompassing local invasion of cancer cells
at primary tumors, intravasation into the blood vessel, survival
in  systemic  circulation,  extravasation,  colonization  and
proliferation at the distant site, and ending with establishment
of growing metastatic lesions [2]. The reduced number of cells
involved  at  each  step  of  the  process  along  with  the
inaccessibility of the relevant anatomical sites has hampered
the study of the mechanisms underlying metastasis. As breast
cancer usually metastasizes to organs such as liver, lung, bone
and brain, the ability to detect microfoci of cancer cells in an
experimental setting is hindered by difficulty in imaging cells in
these internal tissues [3]. In fact, most published studies have
focused on the initial steps of metastasis (local invasion and
intravasation) because they are more accessible for studying in
currently existing animal models [4].
The  use  of  luminescent  and  fluorescent  proteins  and
developments  in  optical  imaging  technology  are  slowly
facilitating the study of the sequential metastatic process [5].
Whole  body  bioluminescence  imaging  enables  the
dissemination of cancer cells through tissues to be monitored
longitudinally  in  the  same  animal  (but  with  low  spatial
resolution),  whereas  intravital  microscopy  (IVM),  through
confocal  or  multiphoton  imaging  of  tumors  expressing
fluorescent  proteins,  enables  spreading  of  a  tumor  to  be
observed  with  subcellular  resolution.  However,  such  IVM
studies usually rely on dorsal skin chambers or reversible skins
flaps  to  increase  sensitivity  of  detection  and  are  therefore
limited  to  the  primary  tumor,  providing  only  information  over
initial  steps  of  metastasis.  Obviously,  this  technique  is  not
suitable  for  following  tumor  progression,  and  internal
metastasis in a live intact animal due to the invasiveness of the
procedure [5].
Consequently,  the  late  steps  in  metastasis  are  poorly
understood.  Therefore,  clarifying  the  molecular  and  cellular
mechanisms  underlying  late  steps  of  the  metastatic  cascade
(i.e. post-arrest events) is a major focus in cancer research. In
addition,  all  available  experimental  data  are  derived  from  in
vivo models where critical steps in hematogenous metastasis
of  human  cancer  cells  (intravasation  and  extravasation)  are
mediated by murine endothelial cells.
Recently, we and others have demonstrated that a network
of  functional  human  blood  vessels  can  be  formed  in
immunodeficient  mice  by  co-implantation  of  primary  human
endothelial  cells  and  human  mesenchymal  cells  (MSC),
embedded  within  a  reconstituted  basement  membrane-like
matrix [6-10]. Here, we demonstrate that BME-rich organoids
containing  functional  microvessels  composed  of  human
endothelial  cells  support  metastatic  colonization  in  an
orthotopic model of breast cancer.
Materials and Methods
Ethics Statement
All experimental procedures were performed in accordance
with the Spanish Government guidelines for the care and use
of  laboratory  animals  and  were  approved  by  the  Hospital
Universitario Puerta de Hierro Animal Care and Use Committee
(CEBA).
Cells
MDA-MB-231 (human breast adenocarcinoma; HTB-26) cells
were  obtained  from  the  American  Type  Culture  Collection
(Rockville, MD, USA) and were cultured in Dulbecco’s modified
Eagle’s  medium  (DMEM)  supplemented  with  10%  heat
inactivated FCS (all from Life Technologies, Gaithersburg, MD,
USA). Human Umbilical Vein Endothelial Cells (HUVEC) were
obtained  from  Lonza  (Walkersville,  MD,  USA)  and  were
cultured in EGM-2 medium containing 2% fetal bovine serum
and endothelial cell growth supplements (Cambrex, Baltimore,
MD, USA). Human bone marrow-derived MSCs were obtained
from  Inbiomed  (San  Sebastian,  Spain)  and  cultured  in  low
glucose DMEM supplemented with 10% FCS of selected lots.
Lentiviral construction
An HIV-derived four-plasmid system was kindly provided by
D. Trono (Department of Microbiology and Molecular Medicine,
University of Geneva, Switzerland). The transfer vector pRRL-
IRES-EGFP contains a cytomegalovirus (CMV) promoter that
drives  an  enhanced-green  fluorescent  protein  (EGFP)
expression cassette [11]. The plasmid pRRL-FLuc-IRES-EGFP
constructed as described previously [6], drives the expression
of  the  firefly  luciferase  (FLuc)  reporter  gene.  To  construct  the
plasmid  pRRL-RLuc-IRES-EGFP,  the  NheI/XbaI  fragment
derived  from  the  plasmid  pRL-CMV  (Promega,  Madison,  WI,
USA) was ligated into the XbaI digested backbone of plasmid
pRRL-IRES-EGFP. The plasmid pRRL-RLuc-IRES-EGFP drives
the  expression  of  the  renilla  luciferase  (RLuc)  reporter  gene.
Lentiviral particles were produced by co-transfection of 293T
cells  through  calcium  phosphate  precipitation,  as  described
[12].
Cell transduction
HUVEC passage 1 in normal growth media were seeded at a
density of 7.5 × 103 cells/cm2, allowed to adhere and infected
overnight with lentivirus (FLuc-IRES-EGFP) at a final multiplicity
of  infection  (MOI)  of  10.  HUVECFluc  were  used  in  vivo  in
passages 3-5. MDA-MB-231 cells in normal growth media were
seeded at a density of 6.25 × 104 cells/cm2, allowed to adhere
and infected overnight with the lentivirus RLuc-IRES-EGFP at a
final MOI of 10.
Cell culture assays for luciferase activity
For  bioluminescence  imaging  (BLI)  of  live  intact  cells
(HUVECFluc or MDA-MB-231Rluc), cell suspensions were serially
diluted  into  appropriate  cell  culture  media  in  96-well  plates
(ranging from 6400 to 100 cells/well) and analyzed in triplicate.
After the addition of 20 µg/well of the appropriate substrate (D-
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quantified using an Infinite 200 microplate luminometer (Tecan,
Switzerland).
Endothelial cell proliferation assay
Endothelial  cell  proliferation  assay  was  performed  by
seeding HUVEC or HUVECFluc (500 cells/well) in 96-well plates
in  complete  HUVEC  medium.  After  24  hours  the  cells  were
switched  to  fresh  EBM-2  basal  medium  with  0.1%  FCS  and
incubated for 24 hours, then the cells were switched to fresh
EBM-2 with 0.5% FCS in the absence or presence of 20 ng/mL
of VEGF (Peprotech, London, UK). The cells were cultured for
an additional 48 hours, and viable cells were detected using
the  MTT  colorimetric  assay  (Sigma-Aldrich,  St.  Louis,  MO,
USA).
Endothelial cell tube formation assay
Basement  Membrane  Extract  (BME)  (Matrigel,  BD
Biosciences) was plated at 4 °C in 96-well plates, and allowed
to gellify for 30 min at 37 °C, then HUVEC or HUVECFluc in 1%
EGM-2 medium, were plated (1.5 x 104 cells/well) and cultured
for  14-16  hours.  Formation  of  capillary-like  structures  was
assessed by bright-field and fluorescence microscopy.
Flow cytometry
For phenotypic analysis cells were treated with appropriate
dilutions of fluorochrome-conjugated mAbs (Table S1) for 30
min at 4  °C. All samples were fixed in 2% formaldehyde and
analyzed with a Beckman-Coulter FC-500 Analyzer (Beckman
Coulter, Fullerton, California, USA).
Animal studies
Six-week-old female athymic nude mice (Hsd: athymic Nude/
Nude;  Harlan  Ibérica,  Barcelona,  Spain)  were  used  for
abdominal  wall  implantation  and  for  xenograft  experiments.
Mice were kept under anesthesia during all manipulations and
all  efforts  were  made  to  minimize  suffering.  Anesthesia  was
induced in an induction chamber with 2.5% isofluorane in 100%
oxygen at a flow rate of 1 L/min and maintained with a 1.5%
mixture at 0.5 L/min. Animals were housed under pathogen-
free conditions and were given irradiated food and autoclaved
water ad libitum. For abdominal implantation of human BME-
rich  vascularized  organoid  (HVO)  a  mixture  (ratio  4:1)  of
HUVECFluc (3 x 105) and MSC (7.5 x 104), were suspended in
150  µl  BME  (Matrigel)  and  inoculated  subcutaneously  in  the
ventral area (right lower quadrant). For abdominal implantation
of  BME-rich  control  organoids  (CO)  150  µl  of  Matrigel  were
inoculated  subcutaneously  in  the  ventral  area  (left  lower
quadrant). All batches of Matrigel were adjusted to 8 mg/ml by
addition  of  PBS  and  supplemented  with  heparin  (128  U/ml)
(Sigma-Aldrich),  human  VEGF  (50  ng/ml)  and  human  bFGF
(150 ng/ml) (both from PeproTech). MDA-MB231Rluc cells (2 x
106)  were  injected  directly  into  the  second  left  mammary  fat
pad  of  each  mouse,  48  hours  after  abdominal  wall  HVO
implantation.  Tumor  growth  and  metastasis  spread  was
monitored every week by RLuc BLI for up to 10 weeks. Tumors
were measured twice weekly using precision calipers. Tumor
volume  was  calculated  using  the  formula:  width2  x  length  x
0.52. The functionality of HVO was monitored every two weeks
by FLuc BLI up to 10 weeks.
In vivo and ex vivo bioluminescence imaging
Mice were imaged using the high-resolution charge-coupled-
device (CCD) cooled digital camera ORCA-2BT (Hamamatsu
Photonics  France,  Massy,  France),  and  Hokawo  software
(Hamamatsu  Photonics).  The  mice  were  anesthetized  using
inhaled isoflurane, as described above, injected i.v. with 125
mg/kg (100 µl) D-luciferin dissolved in PBS or with 900 mg/kg
(100  µl)  coelenterazine-based  compound  dissolved  in  PBS,
and placed on a thermostated bed. BLI was collected with 1
min integration time in FLuc imaging and with 5 min integration
time in RLuc imaging and pseudocolor representations of light
intensity  were  superimposed  over  the  grayscale  reference
image acquired at low light (exposure time 20 ms). An average
of  6  kinetic  BLI  acquisitions  was  collected  after  substrate
injection to confirm a peak of photon emission. For quantitation
of the detected light, regions of interest were drawn and the
light emitted from each region was recorded by recording the
total  number  of  photons  per  second  (total  flux)  after
background  subtraction.  At  the  end  of  each  experiment
anesthetized animals were sacrificed and BME-rich organoids
(CO and HVO), inguinal lymph node and the different organs
(lung, liver and spleen) were rapidly harvested and processed.
Organs  and  BME-rich  organoids  were  placed  in  PBS
containing  coelenterazine-based  compound  and  individually
and  immediately  scanned  for  the  presence  of  RLuc
bioluminescent metastatic cells during 1 min of integration time
as described above.
RNA isolation and real-time quantitative PCR
Total  RNA  isolation  of  tumor  and  organs  was  performed
using  the  RNeasy  Plus  Mini  Kit  (Qiagen  GmbH,  Hilden,
Germany) or the RNeasy Plus Micro Kit (Qiagen) according to
the  weight  of  the  sample  used  for  the  RNA  extraction.  For
disruption  and  homogenization  of  samples,  MagNA  Lyser
Green  Beads  (Roche  Diagnostics,  IN,  USA)  were  used
according  to  the  manufacturer’s  protocol.  cDNA  was
synthesized  using  0.1  mg  of  total  RNA  by  random  primed
reverse transcription with SuperScript VILO cDNA Synthesis kit
for RT–PCR (Roche Applied Science, Germany) according to
the  recommended  protocol.  Real-time  quantitative  PCR  (RT-
qPCR) was performed in a LightCycler 480 apparatus (Roche
Applied  Science)  using  the  LightCycler  480  SYBR  Green  I
Master kit (Roche Applied Science). mRNA expression in each
sample  was  measured  as  a  ratio  against  the  geometric
average of the reference housekeeping human gene succinate
dehydrogenase  complex  subunit  A  (SDHA).  The  relative
concentrations  of  the  target  and  the  reference  genes  were
calculated by interpolation using a standard curve of each gene
plotted  from  the  same  serial  dilution  of  cDNA.  PCR  primers
(Table  S2)  were  designed  with  Primer  Express  software
(Applied  Biosystems,  Foster  City,  CA,  USA)  or  Universal
ProbeLibrary Assay Design Center (Roche Applied Science).
The resulting amplicons had a size of approximately 100 pb.
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Immunohistochemical  analyses  were  performed  on  5  µm
formalin-fixed,  paraffin-embedded  tissue  sections.  Briefly,
samples  were  deparaffinized,  re-hydrated  and  subjected  to
antigen  retrieval  procedures  as  described  previously  [12].  A
histological  section  from  each  initial  tissue  specimen  was
stained  with  hematoxylin  and  eosin  according  to  standard
protocols.  The  mAbs  used  are  listed  in  Table  S3.  Primary
mouse  mAbs  were  detected  with  the  Mouse  on  Mouse
(M.O.M.) peroxidase kit (Vector Laboratories, Burlingame, CA,
USA). Primary rat mAbs were detected with the Vectastain®
ABC kit for rat IgG (Vector Laboratories). As a chromogenic
substrate,  DAB  (Vector  Laboratories)  was  used,  followed  by
hematoxylin  counterstaining.  Staining  was  evaluated  using
Leica DM E microscope (Leica Microsystems, Jena, Germany).
Images  were  acquired  using  Leica  ICC50  HD  camera  and
processed by Leica LAS EZ software. The number of CD45+
cells  was  evaluated  quantitatively  in  four  randomly  chosen
areas of BME-rich organoids (CO and HVO).
Quantitative analyses of vascular morphogenesis
Vascular  structures  in  BME-rich  organoids  (HVO  and  CO)
were classified as either immature or mature vessels. Mature
vessels  were  defined  as  vessel  structures  containing
erythrocytes.  Vascular  morphogenesis  was  quantified  by
enumerating the mature vessels in four randomly chosen fields
and expressing the mean ± SD obtained for each condition. In
order  to  assess  vascular  leakiness,  extravascular  red  blood
cells (RBC) were quantified in four randomly chosen fields and
mean  ±  SD  obtained  for  each  organoid  type  is  shown.
Extravascular RBC are those erythrocytes localized inside the
organoids but unrelated to vascular structures.
Immunofluorescence
Immunofluorescence  analysis  was  performed  on  formalin-
fixed  paraffin-embedded  3  µm  tissue  sections.  After
deparaffinization, heat antigen retrieval was performed in pH
9.0 EDTA-based buffer. Human CD44 was detected using the
rabbit mAb clone EPR1013Y (Table S3) and an Alexa Fluor
655  conjugated  goat  anti-rabbit  IgG  antibody  (Molecular
Probes, Life Technologies). Human CD34 was detected using
the mouse mAb clone QBEnd10 (Table S3), and an Alexa fluor
488 conjugated goat anti-mouse IgG antibody. Sections were
counterstained with DAPI (Abbott Molecular, Abbott, Park, IL,
USA)  to  visualize  cell  nuclei.  Fluorescence  assays  were
performed  at  room  temperature  using  a  Dako  Autostainer
(Dako, Carpinteria, CA, USA). Staining was evaluated by two
investigators  (F.R.  and  S.Z.)  using  a  Leica  fluorescence
DM2000 microscope and images were obtained and processed
by  Nuance  FX  Multispectral  Imaging  System  (CRi,  Caliper,
Hopkinton, MA, USA).
Statistics
The mean and standard deviation (SD) were calculated by
using Prism V (Graphpad Software, San Diego, CA, USA), and
error bars represent the SD. Each experiment was performed a
minimum of three times. The data were evaluated by t test and
were considered to be statistically significant when p <0.05.
Results
Establishment and histological analysis of human
vascularized organoids
Confirming our previous work [6,10] we found that the co-
implantation  of  genetically  modified  human  umbilical  vein
endothelial cells (HUVEC) harboring the firefly luciferase (FLuc)
gene  (HUVECFLuc)  and  human  bone  marrow  derived  MSC
(Figure  S1-S4)  embedded  within  a  reconstituted  basement
membrane  extract  (BME,  also  known  as  Matrigel)
supplemented with VEGF, bFGF and heparin and inoculated
subcutaneously  into  nude  mice  (Figure  1a),  results  in  the
formation  of  mature,  stable  human  blood  vessels.  These
vessels  are  functional,  meaning  that  they  are  able  to
anastomose  with  preexisting  mouse  vessels,  and  can  be
assessed  non-invasively  and  quantitatively  by  in  vivo
bioluminescent  imaging  (BLI)  (Figure  1b).  The  temporal
silencing  of  luciferase  activity  and  subsequent  recovery  is
related to the lapse of time required for the establishment of an
incipient  vascular  network  and  its  integration  into  the  mouse
vascular bed [6].
In  this  paper  we  performed  a  detailed  histological
characterization  of  the  implants.  The  injection  of  150  µl  of
supplemented BME containing HUVECFLuc and MSC, originated
the  formation  of  very  stable  organoids  (Figure  1a),  with
volumes ranging from 13.7 to 25.5 mm3. The mean was 19.8 ±
5.1  (SD).  Two  main  areas  can  be  distinguished:  a  central
homogeneous  region,  with  an  extensive  network  of  perfused
blood vessels (containing erythrocytes; Figure 1c arrowheads)
and  few  non-vascular  cells,  and  a  peripheral  region  with
appreciable  adipogenesis  [13],  in  close  contact  with  the
subcutaneous tissue of the host (Figure 1c). The network of
capillary-like  microvessels  with  a  clear  endothelial  lining  that
expressed  human  CD34,  was  distributed  rather  uniformly
throughout the organoid, while murine vessels were distributed
almost  exclusively  in  the  periphery  of  the  organoid  and  the
surrounding host tissues (Figure 2). Interestingly, some human
blood vessels constituted poorly organized vascular structures
that mimic renal glomeruli (Figure 1c, arrow). These structures
have  been  named  as  “glomeruloid  microvascular
proliferations”, and represent a type of angiogenic blood vessel
[14]. The human vascularized BME-rich organoids (HVO) were
well  tolerated  by  the  host  and  did  not  evoke  adverse
inflammatory responses. A weak inflammatory infiltrate (Figure
S5)  constituted  mainly  by  macrophages  and  neutrophils  was
present in the periphery of the organoid (Figure 2), whereas B
lymphocytes,  NK  cells  and  cells  from  other  hematopoietic
lineages were not present (data not shown). Finally, interstitial
cells  showed  a  myofibroblast  phenotype  [vimentin  and  α-
smooth  muscle  actin  (SMA)],  and  were  interspersed  in  the
organoid  (Figure  2).  Furthermore,  with  the  exception  of  an
increase in vascular density, and adipocyte size and number
(Figure  S6),  the  general  structure  of  the  organoid  and  the
amount of infiltrating cells were unchanged for more than 60
days (Figure S7).
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µl  of  supplemented  BME  alone  resulted  in  the  formation  of
organoids with a volume similar to HVO (average volume 17.6
± 1.6 mm3). However, control organoids (CO) without human
cells  (HUVECFLuc  and  MSC)  were  pale,  indicating  no  or  little
blood  vessel  formation  (Figure  3a).  Histological  analysis
confirmed that the CO were colonized by murine cells but the
degree of vascularization (neo-vessel density and complexity)
was significantly lower than that observed in HVO (p < 0.05,
Figure  S8a).  By  contrast  vascular  leakiness,  quantitatively
assessed  by  counting  the  number  of  extravascular
erythrocytes, was significantly higher in CO (p < 0.05, Figure
S8b and c) than in HVO. A marked adipogenesis was observed
in  all  areas  of  the  CO  sections  (Figure  3b).
Immunohistochemical  staining  demonstrated  that  the
peripheral  region  exhibited  a  dense  CD34  positive  vascular
network  that  contains  luminal  vessels  filled  with  erytrocytes
(Figure  3b  arrowheads),  and  a  weak  inflammatory  infiltrate
(Figure 4) similar to that observed in HVO (Figure S5).
Human vascularized organoids are colonized more
efficiently by disseminated human breast cancer cells
than control organoids
The ability of circulating cancer cells to colonize HVO and
CO was next assessed in an orthotopic model of human breast
cancer.  Implantation  of  MDA-MB-231  human  breast  cancer
cells into the second left mammary fat pad (MFP) of 6-8 weeks
old  female  athymic  nude  mice  is  a  well-characterized
spontaneous  metastasis  model  [15,16].  The  take-rate
percentage  of  genetically  modified  MDA-MB-231  cells
expressing the renilla luciferase (RLuc) gene (MDA-MB-231RLuc)
(Figure  S1-S2)  in  the  MFP  orthotopic  xenograft  model  was
Figure 1.  Generation of BME-rich organoids with functional human blood vessels in immunodeficient mice.  (a) A mixture
of HUVECFLuc (3 x 105) and human MSC (7.5 x 104) were embedded in supplemented BME (150 µl) and inoculated subcutaneously
in the ventral area (right lower quadrant) of immunodeficient mice. Human vascularized BME-rich organoids were easily identified as
small bumps under the skin at all times in vivo. (b) Ventral D-luciferin-based FLuc-BLI images of a representative mouse 1, 2, 4, 7, 10
and 13 weeks after implantation of the human vascularized BME-rich organoid. (c) Low magnification (4x) micrograph displaying the
entire organoid (Scale bar is 1 mm). Hematoxylin and eosin (H and E)-stained sections taken from different part of the organoids
revealed the presence of numerous luminal structures containing erythrocytes (arrowheads), and some glomeruloid microvascular
proliferations (arrows). 10x and 40x images are shown.
doi: 10.1371/journal.pone.0072957.g001
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PLOS ONE | www.plosone.org 5 August 2013 | Volume 8 | Issue 8 | e72957Figure  2.    Immunohistochemical  characterization  of  human  vascularized  BME-rich  organoids.    Immunohistochemical
characterization of explanted human vascularized BME-rich organoids using anti-CD34 (species specific: human and mouse; [39]),
anti-CD45, anti-F4/80, anti-neutrophils, anti-vimentin and anti-α-SMA antibodies (Table S3). Cell nuclei were counterstained with
hematoxylin. 10x and 40x images are shown.
doi: 10.1371/journal.pone.0072957.g002
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subsequent 6–10 weeks (Figure 5a). Mice were evaluated for
primary tumor growth (caliper method and in vivo BLI), HVO
functionality and spontaneous metastasis (in vivo and ex vivo
BLI).
MDA-MB-231RLuc  mammary  tumor  bioluminescence  started
to increase about 3 weeks after tumor cell injection (Figure 5b,
upper panels). Metastatic signals also appeared at that time in
the  left  axillary  region  in  33%  of  the  mice,  indicating
spontaneous  ipsilateral  thoracic  metastasis.  Subsequent
thoracic  images  demonstrated  a  progressive  increase  in
metastatic spread over time, and by week 6 half of the animals
had developed bilateral thoracic metastases, visible by in vivo
BLI (Figure 5b). By 7–10 weeks, metastatic signals appeared in
the  inguinal  region  in  50%  of  the  mice.  HVO  remained
functional  throughout  the  study  period  (Figure  5b,  lower
panels).
Representative ex vivo images are shown in Figure 5c. As
shown  in  Figure  5d  metastases  were  detected  in  lungs,
inguinal lymph nodes and HVO in all mice (n = 8). By contrast
only a third of CO were colonized, while no metastases were
detected in the liver or spleen. Figure 5e shows quantification
of  light  emission  by  excised  tissues.  The  metastatic  burden
was significantly higher in inguinal lymph node and lungs that
in  HVO.  However,  HVO  ex  vivo  signals  were  significantly
higher than those observed in the CO (p < 0.001). Subsequent
histological evaluation confirmed extensive metastases through
the lung tissue. To determine which antibody was best suited to
define  the  metastatic  deposits,  we  performed
immunohistochemical  studies  with  anti-CD44  and  anti-RLuc
antibodies.  MDA-MB-231RLuc  cells  expressed  high  levels  of
CD44 respectively on the cell surface (Figure S9a), whereas
RLuc  was  found  in  the  cytoplasm  (Figure  S9b).  Our  results
indicate that the anti-CD44 mAb provides the best definition of
the metastatic breast cancer cells, and allows the identification
of metastases of varying sizes (Figure S9c).
Figure 3.  Generation of control BME-rich organoids without human cells in immunodeficient mice.  (a) Supplemented BME
(150  μl)  was  inoculated  subcutaneously  in  the  ventral  area  (left  lower  quadrant)  of  immunodeficient  mice.  Control  BME-rich
organoids were easily identified as small bumps under the skin at all times in vivo. (b) Low magnification (4x) micrograph displaying
the entire organoid (Scale bar is 1 mm). Hematoxylin and eosin (H and E)-stained sections taken from different part of the control
organoids revealed the presence of numerous adipocytes, and some luminal structures containing erythrocytes (arrowheads). 10x
and 40x images are shown.
doi: 10.1371/journal.pone.0072957.g003
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PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e72957Figure 4.  Immunohistochemical characterization of control BME-rich organoids.  Immunohistochemical characterization of
explanted control BME-rich organoids using anti-CD34 (species specific: human and mouse; [39]), anti-CD45, anti-neutrophils, anti-
vimentin and anti-α-SMA antibodies (Table S3). Cell nuclei were counterstained with hematoxylin. 10x and 40x images are shown.
doi: 10.1371/journal.pone.0072957.g004
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disseminated tumor cells and micrometastases in
human vascularized organoids
The  presence  of  MDA-MB-231RLuc  cells  in  the  lungs  and
HVOs was assessed as a function of RLuc expression relative to
human  succinate  dehydrogenase  A  (SDHA).  RLuc  and  SDHA
mRNA  levels  were  quantified  by  quantitative  reverse
transcription-PCR.  In  both  cases  RLuc  mRNA  concentrations
were well correlated (r = 0.82 and 0.85, respectively) with ex
vivo bioluminescence (Figure 6).
To further confirm the presence of MDA-MB-231RLuc cells in
the  HVOs,  and  to  study  their  distribution,  we  performed
immunofluorescence studies in those HVO with the highest ex
vivo bioluminescence emission (n = 3). As shown in Figure 7a,
randomly distributed isolated or small clusters (mean = 3.1 ±
1.7 SD) of tumor cells were detected through the HVO inside
the  human  CD34+  microvessels.  These  intravascular  CD44+
cells  were  either  circulating,  attached  to  the  endothelium  or
trapped in the capillary-like microvessels. Notably some of the
intravascular  MDA-MB-231RLuc  cells  traversed  the  human
vascular  wall  to  colonize  the  surrounding  matrix  (Figure  7a).
Moreover, in addition to these micrometastases we identified
larger growing metastases, composed by 40-50 CD44+ tumor
cells adjacent to blood vessels of human origin (Figure 7b).
Discussion
We  have  herein  described  a  new  mouse  model  to  study
metastatic colonization, and we demonstrate that disseminated
human  breast  cancer  cells  efficiently  colonize  BME-rich
organoids  containing  a  functional  microvessel  network
composed of human endothelial cells connected to the mouse
Figure 5.  Spontaneous metastasis from primary mammary fat pad tumors.  MDA-MB-231RLuc human breast cancer cells were
implanted into the orthotopic environment of the left axillary MFP of nude mice bearing human vascularized BME-rich organoids
(HVO) and control BME-rich organoids (CO), without human cells. Primary tumor growth (a, b), metastatic spread (b-e) and HVO
functionality (b, c) were monitored over time in vivo and ex vivo. (a) Tumor growth curves for MDA-MB-231RLuc (n = 10) orthotopic
mammary tumors. (b) In vivo ventral coelenterazine-based RLuc-BLI images (upper panels) and D-luciferin-based FLuc-BLI images
(lower panels) of a representative mouse. (c) Ex vivo coelenterazine-based RLuc-BLI images (upper panels) and D-luciferin-based
FLuc-BLI images (lower panels) of excised lungs, inguinal lymph node (LN), spleen, liver, HVO and CO of a representative mouse.
(d)  Percentage  of  metastatic  colonization  and  (e)  tumor  burden  in  harvested  tissues  (normal  mouse  organs  and  BME-rich
organoids) of mice (n = 8) with primary tumor growth. Significant differences (*** p < 0.001).
doi: 10.1371/journal.pone.0072957.g005
A New Mouse Model to Study Cancer Metastasis
PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e72957circulatory system. Despite their apparent structural simplicity,
HVO  were  efficiently  colonized  by  MDA-MB-231  cells,  and
importantly, human breast cancer cells could be unequivocally
detected at different stages of the metastatic process: initial cell
arrest  in  human  capillaries,  extravasation,  and  growth  from
avascular  micrometastases  to  vascularized  micrometastases
growing  into  the  surrounding  BME.  In  control  BME-rich
organoids  without  human  cells,  the  number  of  vessels  was
lower  than  in  the  HVO  and  these  were  more  immature  and
leaky.  Despite  increased  leakiness  of  vessels  in  CO,  the
percentage  of  metastatic  colonization  was  significantly  lower
than that observed in HVO, although we cannot rule out that
differences  in  microvascular  density  may  contribute  to
differences in the number of metastasis.
Tumor-derived BME has been used for more than 20 years
in models (both in vitro and in vivo) of angiogenesis, invasion
and  primary  tumor  growth  [15-17].  Proteomics  analysis  of
tumor-derived BME resulted in the identification of 1302 unique
proteins [20], but in fact it is composed mainly of laminin-111
(56%),  collagen  IV  (31%),  entactin  (8%)  and  perlecan  (4%)
Figure  6.    Correlation  between  mRNA  levels  of  Renilla  Luciferase  (RLuc)  and  ex  vivo  coelenterazine-based  RLuc-
bioluminescence  of  lungs  (n  =  4)  and  human  vascularized  BME-rich  organoids  (n  =  5).    In  both  cases  RLuc  mRNA
concentrations were well correlated (a: r = 0.829; b: r = 0.851) with ex vivo bioluminescence data.
doi: 10.1371/journal.pone.0072957.g006
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“basement  membrane  toolkit”  [22],  which  is  found  in  most
metazoans and has been shown to be crucial to their evolution.
Given  that  the  basement  membrane  is  the  first  extracellular
matrix  (ECM)  produced  in  the  developing  embryo,  it  was
quickly  identified  as  an  important  factor  for  modulating  stem
cell  behavior  [23],  that  plays  multiple  roles  in  the  stem  cell
niche. It is perhaps not surprising then that BME is the gold
standard  for  the  maintenance  of  a  wide  array  of  human
embryonic  stem  cell  (hESC)  lines,  as  it  contains  all  of  the
proteins that have been shown to promote hESC growth when
used individually [24].
Furthermore, increasing evidence suggests that the ECM is
also a key component of the cancer stem cell niche [25]. In
fact,  the  ECM  not  only  promotes  cancer  cell  growth  at  the
primary site but also provide signals that support metastatic cell
survival,  colonization  and  proliferation  [25].  Several  reports
have  recently  revealed  that  the  ECM  proteins  fibronectin,
tenascin-C,  periostin  and  versican  play  essential  roles  as
components  of  the  metastatic  niche  for  tumor-initiating  cells
that invade the lungs [25–29]. Not surprisingly, BME has been
widely used to test the metastatic potential of cancer cells in
vitro [18].
During the past several years, a crucial role for bone-marrow
derived cells in priming distant tissues for tumor engraftment
has been uncovered [26]. VEGFR1+ hematopoietic progenitor
cells are mobilized and recruited early during the formation of
pre-metastatic  niche  [26].  A  causal  relationship  between
Figure 7.  Detection of disseminated tumor cells in human vascularized BME-rich organoids.  sections. (a) The parenchyma
contains a network of human CD34+ capillary-like microvessels (in green) and numerous isolated or clusters of CD44+ MDA-MB-231
tumor cells (in red), which are circulating (white arrow), attached to the endothelium (yellow arrow) or extravasating and colonizing
the  surrounding  matrix  (asterisk).  (b)  Small  foci  of  CD44+  MDA-MB-231  tumor  cells  adjacent  to  human  CD34+  capillary-like
microvessels and glomeruloid microvascular proliferations. Nuclei are labeled in DAPI, x200. Scale bar is 25 μm.
doi: 10.1371/journal.pone.0072957.g007
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proposed [30], and accordingly a variety of inflammatory cells
(CD11b+ myelod cells, monocytes/macrophages, lymphocytes
and neutrophils) that drive primary tumor growth may have an
important  role  in  metastatic  colonization  [31,32].  In  addition
stromal  cells  [33,34]  and  endothelial  cells  [35,36]  also
participate  in  the  metastatic  niche.  Although  we  have  not
studied the contribution of host-derived cells in the colonization
of HVO, this model could be an ideal system for studying the
role  of  different  cell  types  in  the  process  of  metastatic
colonization.
Molecular  interactions  between  human  breast  cancer  cells
and murine endothelial cells may not recapitulate those taking
place during intravasation and extravasation of cancer cells in
patients.  For  this  reason,  we  estimate  that  mice  carrying
human  vascularized  BME-rich  organoids  would  be  a  more
suitable  model  for  studying  the  interactions  between
disseminated  cancer  cells  and  host  endothelium.  In  fact,  a
murine microenvironment is not always a “congenial soil” for
metastatic human cells [37]. For example, in a mouse model of
human  breast  cancer,  bone  metastases  were  more  frequent
when  the  target  organ  was  of  human  origin,  suggesting  a
species-specific tropism [38].
In  summary,  we  have  described  here  the  generation  and
characterization  of  a  simple,  non-invasive  mouse  model  that
could  more  accurately  recapitulate  human  breast  cancer
metastasis,  and  could  be  easily  adapted  for  intravital
microscopy. Although this model is still artificial, it may help to
assess  the  cancer  cell  extravasation  step  in  a  more
physiological  setting  than  previous  models,  opening  new
avenues  to  the  development  of  innovative  anti-cancer
strategies.
Supporting Information
Figure  S1.    Schematic  representation  of  lentiviral
bicistronic vectors. Schematic representation of the lentiviral
bicistronic  vectors  pRRL-FLuc-IRES-EGFP  containing  firefly
luciferase  (FLuc)  and  enhanced-green  fluorescent  protein
(EGFP)  genes  (a),  and  pRRL-RLuc-IRES-EGFP  containing
renilla luciferase (RLuc) and EGFP genes (b). LTR, long terminal
repeat; ΔGAG, ATG-deleted group-specific antigen; RRE, Rev-
responsive element; EMCV IRES, encephalomyocarditis virus
internal ribosomal entry site.
(TIF)
Figure  S2.    EGFP  expression  and  bioluminescent
properties  of  HUVECFLuc  and  MDA-MB-231RLuc  cells.  Flow
cytometry  analysis  showing  EGFP  expression  by  lentivirally
transduced  HUVECFLuc  (a)  or  MDA-MB-231RLuc  (c)  cells.
Bioluminescent  properties  of  HUVECFLuc  (b)  or  MDA-
MB-231RLuc cells (d) in the presence and absence of substrate
(D-luciferin or coelenterazine). Luciferase activity is expressed
as relative light units (RLU). Data represent the average ± SD
of triplicate samples.
(TIF)
Figure  S3.    Comparative  study  of  wild-type  HUVEC  and
lentivirally transduced HUVECFLuc. Flow cytometry alaysis of
CD34  or  CD31  expression  (Table  S1)  on  HUVEC  (a)  and
HUVECFLuc  (b).  Isotype-matched  antibodies  were  used  as
control (grey line). VEGF significantly induced HUVEC (c) and
HUVECFLuc (d) proliferation. Data represent the mean ± SD of
triplicate samples. The differences were statistically significant
(*p < 0.05, **p < 0.01). Formation of capillary-like structures by
HUVEC  (e)  and  HUVECFLuc  (f)  cultured  for  14-16  h  on
reconstituted Matrigel.
(TIF)
Figure  S4.    Phenotype  of  bone  marrow-derived  human
MSC.  Cells  were  trypsinized,  labeled  with  antibodies  against
the  indicated  antigens  (Table  S1)  and  analyzed  by  flow
cytometry.  Isotype-matched  antibodies  were  used  as  control
(grey line).
(TIF)
Figure S5.  Comparative analysis of CD45+ cells in human
vascularized and control BME-rich organoids.
Mean ± SD of cells stained with anti-CD45 antibody (Table S3)
in four randomly chosen fields (n = 3).
(TIF)
Figure  S6.    Temporal  changes  in  mature  vessel  density
and in the total adipocyte number in human vascularized
BME-rich  organoids.  Temporal  changes  in  mature  vessel
density  (mean  ±  SD  of  perfused  vessels  in  four  randomly
chosen fields, n = 3) (a), and the number of adipocytes per
square millimeter (mean ± SD, n = 3) (b).
(TIF)
Figure  S7.    Hematoxylin  and  eosin-stained  sections  of
human  vascularized  BME-rich  organoids.  15  days  (a),  30
days (b), and 45 days after implantation. 4x and 10x images
are shown.
(TIF)
Figure S8.  Comparative analysis of mature vessel density
and vascular leakiness in human vascularized and control
BME-rich organoids 30 days after implantation. (a) Mean ±
SD of perfused vessels in four randomly chosen fields (n = 3).
(b) Mean ± SD of extravascular red blood cells (RBC) in four
randomly chosen fields (n = 3). Significant differences (* p <
0.05).  (c)  Hematoxylin  and  eosin-stained  sections  and
immunohystochemical characterization of explanted BME-rich
human  vascularized  and  control  organoids  using  anti-CD34
(species specific: human and mouse [39]).
(TIF)
Figure  S9.    Characterization  of  antibodies  against  CD44
and Renilla Luciferase (RLuc). (a) Cell surface expression of
CD44  (MEM-85)  in  MDA-MB-231RLuc  cells.  (b-c)
Immunohistochemical  staining  of  lung  metastases.  Serial
sections of lung tissue were stained for CD44 (F10-44-2) and
RLuc. 10x and 40x images are shown.
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Table  S1.    Fluorochrome-conjugated  monoclonal
antibodies.
(DOCX)
Table S2.  Primer pairs used for real-time quantitative RT-
PCR.
(DOCX)
Table S3.  Unconjugated monoclonal antibodies.
(DOCX)
Acknowledgements
We  thank  Erkki  Ruoslahti  and  Richard  G.  Vile  for  helpful
discussions and for critically reading the manuscript.
Author Contributions
Conceived and designed the experiments: LS LAV. Performed
the  experiments:  RFP  IMP  FR  IGM  VAC  SZ  MC  AAC  ACM
DSM. Analyzed the data: RFP IMP FR SZ AAM. Contributed
reagents/materials/analysis tools: AAM. Wrote the manuscript:
FR LS LAV.
References
1. Weigelt B, Peterse JL, van ’t Veer LJ (2005) Breast cancer metastasis:
markers  and  models.  Nat  Rev  Cancer  5:  591–602.  doi:10.1038/
nrc1670. PubMed: 16056258.
2. Nguyen  DX,  Bos  PD,  Massagué  J  (2009)  Metastasis:  from
dissemination to organ-specific colonization. Nat Rev Cancer 9: 274–
284. doi:10.1038/nrc2622. PubMed: 19308067.
3. Brackstone M, Townson JL, Chambers AF (2007) Tumour dormancy in
breast  cancer:  an  update.  Breast  Cancer  Res  9:  208.  doi:10.1186/
bcr1677. PubMed: 17561992.
4. Kim IS, Baek SH (2010) Mouse models for breast cancer metastasis.
Biochem  Biophys  Res  Commun  394:  443–447.  doi:10.1016/j.bbrc.
2010.03.070. PubMed: 20230796.
5. Sahai E (2007) Illuminating the metastatic process. Nat Rev Cancer 7:
737–749. doi:10.1038/nrc2229. PubMed: 17891189.
6. Sanz L, Santos-Valle P, Alonso-Camino V, Salas C, Serrano A et al.
(2008) Long-term in vivo imaging of human angiogenesis: critical role of
bone  marrow-derived  mesenchymal  stem  cells  for  the  generation  of
durable blood vessels. Microvasc Res 75: 308–314. doi:10.1016/j.mvr.
2007.11.007. PubMed: 18252255.
7. Au  P,  Tam  J,  Fukumura  D,  Jain  RK  (2008)  Bone  marrow-derived
mesenchymal stem cells facilitate engineering of long-lasting functional
vasculature.  Blood  111:  4551–4558.  doi:10.1182/
blood-2007-10-118273. PubMed: 18256324.
8. Melero-Martin JM, Khan ZA, Picard A, Wu X, Paruchuri S et al. (2007)
In  vivo  vasculogenic  potential  of  human  blood-derived  endothelial
progenitor  cells.  Blood  109:  4761–4768.  doi:10.1182/
blood-2006-12-062471. PubMed: 17327403.
9. Melero-Martin JM, De Obaldia ME, Kang S-Y, Khan ZA, Yuan L et al.
(2008) Engineering robust and functional vascular networks in vivo with
human  adult  and  cord  blood-derived  progenitor  cells.  Circ  Res  103:
194–202. doi:10.1161/CIRCRESAHA.108.178590. PubMed: 18556575.
10. Compte M, Alonso-Camino V, Santos-Valle P, Cuesta AM, Sánchez-
Martín D et al. (2010) Factory neovessels: engineered human blood
vessels secreting therapeutic proteins as a new drug delivery system.
Gene Ther 17: 745–751. doi:10.1038/gt.2010.33. PubMed: 20336155.
11. Compte  M,  Blanco  B,  Serrano  F,  Cuesta  AM,  Sanz  L  et  al.  (2007)
Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-
CEA  x  anti-CD3  diabodies  from  lentivirally  transduced  human
lymphocytes.  Cancer  Gene  Ther  14:  380–388.  doi:10.1038/sj.cgt.
7701021. PubMed: 17218946.
12. Alonso-Camino V, Santos-Valle P, Ispizua MC, Sanz L, Alvarez-Vallina
L (2011) Engineered human tumor xenografts with functional human
vascular  networks.  Microvasc  Res  81:  18–25.  doi:10.1016/j.mvr.
2010.10.002. PubMed: 20934439.
13. Kawaguchi N, Toriyama K, Nicodemou-Lena E, Inou K, Torii S et al.
(1998)  De  novo  adipogenesis  in  mice  at  the  site  of  injection  of
basement membrane and basic fibroblast growth factor. Proc Natl Acad
Sci  U  S  A  95:  1062–1066.  doi:10.1073/pnas.95.3.1062.  PubMed:
9448285.
14. Nagy JA, Chang S-H, Dvorak AM, Dvorak HF (2009) Why are tumour
blood vessels abnormal and why is it important to know? Br J Cancer
100: 865–869. doi:10.1038/sj.bjc.6604929. PubMed: 19240721.
15. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W et al. (2005) Genes
that mediate breast cancer metastasis to lung. Nature 436: 518–524.
doi:10.1038/nature03799. PubMed: 16049480.
16. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW et al. (2007)
Mesenchymal stem cells within tumour stroma promote breast cancer
metastasis. Nature 449: 557–563. doi:10.1038/nature06188. PubMed:
17914389.
17. Arnaoutova  I,  George  J,  Kleinman  HK,  Benton  G  (2009)  The
endothelial cell tube formation assay on basement membrane turns 20:
state  of  the  science  and  the  art.  Angiogenesis  12:  267–274.  doi:
10.1007/s10456-009-9146-4. PubMed: 19399631.
18. Albini A, Noonan DM (2010) The “chemoinvasion” assay, 25 years and
still  going  strong:  the  use  of  reconstituted  basement  membranes  to
study cell invasion and angiogenesis. Curr Opin Cell Biol 22: 677–689.
doi:10.1016/j.ceb.2010.08.017. PubMed: 20822888.
19. Benton G, Kleinman HK, George J, Arnaoutova I (2011) Multiple uses
of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo
with cancer cells. Int J Cancer 128: 1751–1757. doi:10.1002/ijc.25781.
PubMed: 21344372.
20. Hughes CS, Postovit LM, Lajoie GA (2010) Matrigel: a complex protein
mixture  required  for  optimal  growth  of  cell  culture.  Proteomics  10:
1886–1890. doi:10.1002/pmic.200900758. PubMed: 20162561.
21. Patel VN, Knox SM, Likar KM, Lathrop CA, Hossain R et al. (2007)
Heparanase cleavage of perlecan heparan sulfate modulates FGF10
activity during ex vivo submandibular gland branching morphogenesis.
Development  134:  4177–4186.  doi:10.1242/dev.011171.  PubMed:
17959718.
22. Whittaker  DR,  Fillinger  MF  (2006)  The  engineering  of  endovascular
stent  technology:  a  review.  Vasc  Endovasc  Surg  40:  85–94.  doi:
10.1177/153857440604000201. PubMed: 16598355.
23. Arnaoutova  I,  George  J,  Kleinman  HK,  Benton  G  (2012)  Basement
membrane matrix (BME) has multiple uses with stem cells. Stem Cell
Rev 8: 163–169. doi:10.1007/s12015-011-9278-y. PubMed: 21655946.
24. Hughes CS, Nuhn AA, Postovit LM, Lajoie GA (2011) Proteomics of
human  embryonic  stem  cells.  Proteomics  11:  675–690.  doi:10.1002/
pmic.201000407. PubMed: 21225999.
25. Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: A dynamic
niche in cancer progression. J Cell Biol 196: 395–406. doi:10.1083/jcb.
201102147. PubMed: 22351925.
26. Kaplan  RN,  Riba  RD,  Zacharoulis  S,  Bramley  AH,  Vincent  L  et  al.
(2005)  VEGFR1-positive  haematopoietic  bone  marrow  progenitors
initiate  the  pre-metastatic  niche.  Nature  438:  820–827.  doi:10.1038/
nature04186. PubMed: 16341007.
27. Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr H-A et al.
(2012) Interactions between cancer stem cells and their niche govern
metastatic colonization. Nature 481: 85–89. PubMed: 22158103.
28. Oskarsson  T,  Massagué  J  (2012)  Extracellular  matrix  players  in
metastatic niches. EMBO J 31: 254–256. PubMed: 22179697.
29. Gao  D,  Joshi  N,  Choi  H,  Ryu  S,  Hahn  M  et  al.  (2012)  Myeloid
progenitor  cells  in  the  premetastatic  lung  promote  metastases  by
inducing mesenchymal to epithelial transition. Cancer Res 72: 1384–
1394. doi:10.1158/1538-7445.AM2012-1384. PubMed: 22282653.
30. Mantovani A, Marchesi F, Portal C, Allavena P, Sica A (2008) Linking
inflammation  reactions  to  cancer:  novel  targets  for  therapeutic
strategies.  Adv  Exp  Med  Biol  610:  112–127.  doi:
10.1007/978-0-387-73898-7_9. PubMed: 18593019.
31. Lukanidin  E,  Sleeman  JP  (2012)  Building  the  niche:  the  role  of  the
S100 proteins in metastatic growth. Semin Cancer Biol 22: 216–225.
doi:10.1016/j.semcancer.2012.02.006. PubMed: 22381352.
32. Hiratsuka  S,  Watanabe  A,  Aburatani  H,  Maru  Y  (2006)  Tumour-
mediated upregulation of chemoattractants and recruitment of myeloid
cells predetermines lung metastasis. Nat Cell Biol 8: 1369–1375. doi:
10.1038/ncb1507. PubMed: 17128264.
A New Mouse Model to Study Cancer Metastasis
PLOS ONE | www.plosone.org 13 August 2013 | Volume 8 | Issue 8 | e7295733. Psaila B, Lyden D (2009) The metastatic niche: adapting the foreign
soil.  Nat  Rev  Cancer  9:  285–293.  doi:10.1038/nrc2621.  PubMed:
19308068.
34. Duda DG, Duyverman AMMJ, Kohno M, Snuderl M, Steller EJA et al.
(2010) Malignant cells facilitate lung metastasis by bringing their own
soil. Proc Natl Acad Sci U S A 107: 21677–21682. doi:10.1073/pnas.
1016234107. PubMed: 21098274.
35. DeLisser  H,  Liu  Y,  Desprez  P-Y,  Thor  A,  Briasouli  P  et  al.  (2010)
Vascular  endothelial  platelet  endothelial  cell  adhesion  molecule  1
(PECAM-1) regulates advanced metastatic progression. Proc Natl Acad
Sci USA 107: 18616–18621. doi:10.1073/pnas.1004654107. PubMed:
20926749.
36. Reymond N, Im JH, Garg R, Vega FM, Borda d’Agua B et al. (2012)
Cdc42 promotes transendothelial migration of cancer cells through β1
integrin. J Cell Biol 199: 653–668.
37. Fantozzi  A,  Christofori  G  (2006)  Mouse  models  of  breast  cancer
metastasis. Breast Cancer Res 8: 212. doi:10.1186/bcr1530. PubMed:
16887003.
38. Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K et al.
(2005) A mouse model of human breast cancer metastasis to human
bone.  Cancer  Res  65:  6130–6138.  doi:
10.1158/0008-5472.CAN-04-1408. PubMed: 16024614.
39. Sanz  L,  Cuesta  AM,  Salas  C,  Corbacho  C,  Bellas  C  et  al.  (2009)
Differential  transplantability  of  human  endothelial  cells  in  colorectal
cancer and renal cell carcinoma primary xenografts. Lab Invest 89: 91–
97. doi:10.1038/labinvest.2008.108. PubMed: 19002108.
A New Mouse Model to Study Cancer Metastasis
PLOS ONE | www.plosone.org 14 August 2013 | Volume 8 | Issue 8 | e72957